Immunohistochemical analyses of tumor tissue indicated that treatment with eliglustat statistically significantly reduced Cav-1 and PCNA staining (two-sided Wilcoxon rank sum test p: 0.008 and 0.001, respectively), whereas BrdU-TUNEL and mitophagy-associated marker (LC3B and HMGB1)48,49 staining was statistically significantly increased (two-sided Wilcoxon rank sum test p: 0.008 for all three markers) (Fig. 7f). The gene discussed is MAP1LC3B; the disease is neoplasm.